Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary Aug 5, 2021 Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
LAWRENCEVILLE, N.J. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.
View HTML
PDF Version
Toggle Summary Jul 29, 2021 Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
Data show d ose - dependent suppression of immun e- suppressive agents GEN-1 stimulate s the immune system through the production of CD4 and CD8 cells C hemotherapy R esponse Score tripled in the two highest doses of GEN-1 and is double that of chemotherapy alone LAWRENCEVILLE, N.J.
View HTML
PDF Version
Toggle Summary Jul 19, 2021 Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene- M ediated Immunotherapy is Safe and Demonstrates an Acceptable   R isk/ B enefit W hen Administered O ver a Six-Month   Period   with   Up to 17 D oses LAWRENCEVILLE, N.J.
View HTML
PDF Version
Toggle Summary Jul 15, 2021 Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage
View HTML
PDF Version
Toggle Summary Jul 1, 2021 Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
LAWRENCEVILLE, N.J. , July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , Celsion GmbH , a wholly owned subsidiary of Celsion Corporation , a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox study with ThermoDox ® in
View HTML
PDF Version
Toggle Summary Jun 23, 2021 Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
Celsion GmbH   will manage current and future cancer studies with Thermo D ox ® Celsion   continues its strategic   focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J. , June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on
View HTML
PDF Version
Toggle Summary Jun 21, 2021 Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank
Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and   Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. , June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based
View HTML
PDF Version
Toggle Summary Jun 9, 2021 Celsion Appoints Christine A. Pellizzari to its Board of Directors
Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J. , June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy
View HTML
PDF Version
Toggle Summary Jun 8, 2021 Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez , MD LAWRENCEVILLE, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines,
View HTML
PDF Version
Toggle Summary Jun 4, 2021 CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
49% of S hares V oted, Q uorum N ot E stablished   To Hold Annual Meeting Polls Remain Open Stockholders H olding U nvoted Proxies A re S trongly E ncouraged to V ote T heir S hares LAWRENCEVILLE, N.J. , June 04, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage
View HTML
PDF Version

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • LinkedIn
    • Twitter
    • RSS

Celsion
Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

LinkedIn

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2022 Celsion Corporation. All rights reserved.

    • Twitter
    • Facebook
    • LinkedIn
    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn